Zuern Allison, Probst Luke A, Darko William, Rosher Peter, Miller Christopher D, Gordon Lori, Seabury Robert
State University of New York Upstate University Hospital, Syracuse, USA.
Hosp Pharm. 2020 Aug;55(4):240-245. doi: 10.1177/0018578719841035. Epub 2019 Apr 4.
Regular insulin is a commonly utilized treatment option for acute hyperkalemia. Despite its benefit, hypoglycemia and associated morbidity/mortality remain important concerns. This institution recently created a treatment panel to standardize regular insulin dosing (0.1 unit/kg) and blood glucose (BG) monitoring in patients with acute hyperkalemia. The purpose of this study is to investigate whether the order panel reduces hypoglycemic events in adults treated with intravenous (IV) regular insulin for hyperkalemia and to determine the effect the treatment panel has on regular insulin dosing, serum potassium, BG monitoring, and dextrose supplementation. This retrospective study was performed at a single academic medical center. Adults receiving IV regular insulin for acute hyperkalemia were included if BG was assessed prior to and following regular insulin administration. Primary outcome was hypoglycemia within 4 hours of regular insulin administration. Secondary outcomes were the change from baseline serum potassium, frequency of severe hypoglycemia, BG checks within 30 minutes prior to and within 4 hours following insulin administration, regular insulin dosing, and administration of dextrose 50% in water (D50W) following regular insulin administration. Hypoglycemia and severe hypoglycemia were defined as a BG concentration of <70 mg/dL and <50 mg/dL, respectively. One hundred sixty-five patients were included; 75 using the treatment panel and 90 not. Patients using the treatment panel received a lower median (interquartile range [IQR]) regular insulin dose (.10 [0.09-0.10 unit/kg] vs 0.11 [0.09-0.14 unit/kg], = .004) and had more frequent BG checks during the 4 hours following regular insulin administration (median [IQR]: 4 [3-5] vs 2 [1-3], < .001). Hypoglycemia (13.3% vs 27.8%, = .024) and severe hypoglycemia (2.7% vs 11.1%, = .038) occurred less frequently with the treatment panel. Similar decreases in serum potassium were noted following IV regular insulin administration. Acute hyperkalemic patients utilizing a standardized treatment panel for the dosing and monitoring of IV regular insulin experienced fewer hypoglycemic and severe hypoglycemic episodes and had similar potassium lower effects. The treatment panel decreased regular insulin dosing and increased BG monitoring prior to and following regular insulin administration.
普通胰岛素是治疗急性高钾血症常用的一种治疗选择。尽管有其益处,但低血糖及相关的发病率/死亡率仍是重要的关注点。该机构最近设立了一个治疗小组,以规范急性高钾血症患者普通胰岛素的给药剂量(0.1单位/千克)和血糖(BG)监测。本研究的目的是调查该医嘱小组是否能减少接受静脉注射(IV)普通胰岛素治疗高钾血症的成人患者的低血糖事件,并确定该治疗小组对普通胰岛素给药剂量、血清钾、BG监测和葡萄糖补充的影响。这项回顾性研究在一家学术医疗中心进行。如果在普通胰岛素给药前后评估了BG,则纳入接受IV普通胰岛素治疗急性高钾血症的成人患者。主要结局是普通胰岛素给药后4小时内发生的低血糖。次要结局包括血清钾相对于基线的变化、严重低血糖的发生率、胰岛素给药前30分钟内及给药后4小时内的BG检查次数、普通胰岛素给药剂量以及普通胰岛素给药后50%葡萄糖溶液(D50W)的使用情况。低血糖和严重低血糖分别定义为BG浓度<70mg/dL和<50mg/dL。共纳入165例患者;75例使用治疗小组,90例未使用。使用治疗小组的患者接受的普通胰岛素中位剂量(四分位间距[IQR])较低(0.10[0.09 - 0.10单位/千克]对0.11[0.09 - 0.14单位/千克],P = 0.004),且在普通胰岛素给药后的4小时内进行BG检查的频率更高(中位值[IQR]:4[3 - 5]对2[1 - 3],P < 0.001)。治疗小组发生低血糖(13.3%对27.8%,P = 0.024)和严重低血糖(2.7%对11.1%,P = 0.038)的频率较低。静脉注射普通胰岛素后,血清钾也有类似程度的下降。使用标准化治疗小组进行IV普通胰岛素给药和监测的急性高钾血症患者发生低血糖和严重低血糖事件的次数较少,且降低血钾的效果相似。该治疗小组减少了普通胰岛素给药剂量,并增加了普通胰岛素给药前后的BG监测。